Compare OLN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLN | NUVB |
|---|---|---|
| Founded | 1892 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | OLN | NUVB |
|---|---|---|
| Price | $20.36 | $8.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $24.57 | $9.63 |
| AVG Volume (30 Days) | 2.4M | ★ 10.2M |
| Earning Date | 01-29-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $6,787,000,000.00 | $26,748,000.00 |
| Revenue This Year | $3.82 | $609.55 |
| Revenue Next Year | $2.15 | $197.91 |
| P/E Ratio | $43.75 | ★ N/A |
| Revenue Growth | 4.68 | ★ 1137.19 |
| 52 Week Low | $17.66 | $1.54 |
| 52 Week High | $43.33 | $8.95 |
| Indicator | OLN | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 67.00 |
| Support Level | $20.00 | $7.46 |
| Resistance Level | $21.80 | $8.95 |
| Average True Range (ATR) | 0.90 | 0.67 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 59.89 | 78.26 |
Olin Corp manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on the product type. The Chlor alkali products and Vinyls segment, which generates the majority of revenue, sells chlorine and caustic soda, which are used in a variety of industries including cosmetics, textiles, crop protection, and fire protection products. The Epoxy segment sells epoxy resins used in paints and coatings. The Winchester segment sells sporting ammunition and ammunition accessories under the Winchester brand. The majority of revenue comes from the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.